7/18 Earnings Preview: Valeant Pharmaceuticals •Valeant progressed in its turnaround by applying asset sales to lower its debt. •Even an analyst downgrade failed to hurt VRX's stock price. •Fair value updated. https://seekingalpha.com/article/4088372-earnings-preview-valeant-pharmaceuticals?auth_param=1vat:1cms1gf:f61fa6db4aec9f21cf31ba4858a685c2&uprof=51